Steven L Bernstein

US Patent:

8106096, Jan 31, 2012

Filed:

Mar 12, 2009

Appl. No.:

12/402833

Inventors:

Steven L Bernstein - Chevy Chase MD, US

Assignee:

University of Maryland, Baltimore - Baltimore MD

International Classification:

A61K 31/5575

US Classification:

514573

Abstract:

The present invention provides a method for treating or reducing damage to the optic nerve in a subject comprising administering to the subject a therapeutically effective amount of prostaglandin J2 alone or in combination with an effective amount of GM-CSF. In particular aspects of the invention, the subject is a mammal, and in further aspects the mammal is a human.

US Patent:

20020108129, Aug 8, 2002

Filed:

Feb 7, 2001

Appl. No.:

09/727603

Inventors:

Steven Bernstein - Chevy Chase MD, US

International Classification:

A01K067/00
A61K049/00

US Classification:

800/003000, 424/009200

Abstract:

Anterior ischemic optic neuropathy (AION) is one of a family of ischemic diseases affecting the optic nerve. A blockage of vessels supplying the intra-retinal portion of the optic nerve results in loss of axon transport stasis, retinal ganglion cell (RGC)—specific dysfunction, and RGC death. AION research has been limited by the lack of a low-cost model for this disease. The invention of such a model has now been developed. Using a custom contact lens, an intravenous injection of photosensitizing agent is administered to anesthetize male Sprague-Dawley rats. A laser was used to activate dye within the small vessels perfusing the optic nerve. This treatment was adjusted to spare the larger caliber vessels perfusing the inner retina. Electrophysiologically, a decrease in amplitude of the visual evoked potential is noted. Histologically, alterations in axonal transport are seen. Polymerase chain reactions (rt-PCR) indicate that there are both early RGC-specific, and later retinal gene expression changes in the treated animals. This method replicates many cellular and molecular level changes in a low-cost animal model.

US Patent:

20040228795, Nov 18, 2004

Filed:

Jun 15, 2004

Appl. No.:

10/868600

Inventors:

Steven Bernstein - Chevy Chase MD, US

International Classification:

A61K049/00
A61K031/555
A61N001/30

US Classification:

424/009200, 514/185000, 604/020000

Abstract:

Anterior ischemic optic neuropathy is an ischemic disease affecting the optic nerve. A blockage of vessels supplying the intra-retinal portion of the optic nerve causes loss of axon transport stasis, retinal ganglion cell, specific dysfunction, and RGC death. Research has been limited by the lack of low-cost models for this disease. Using a custom contact lens, an intravenous injection of photosensitizing agent anesthetizes male Sprague-Dawley rats. A laser activate dye within the small vessels perfusing the optic nerve. This treatment spared the larger vessels perfusing the inner retina. Electropliysiologically, a decrease in amplitude of the visual evoked potential is noted. Histologically, alterations in axonal transport are seen. Reverse-transcriptase based Polymerase chain later retinal gene expression changes in treated animals. This method replicates many cellular and molecular level changes in a low-cost animal model.

US Patent:

20220175844, Jun 9, 2022

Filed:

Feb 1, 2019

Appl. No.:

16/966204

Inventors:

Steven BERNSTEIN - Chevy Chase MD, US
Candace L. KERR - Westminster MD, US
Sally A. TEMPLE - Slingerlands NY, US
- Baltimore MD, US
- Rensselaer NY, US

Assignee:

University of Maryland, Baltimore - Baltimore MD
REGENERATIVE RESEARCH FOUNDATION - Rensselaer NY

International Classification:

A61K 35/30
A61K 38/18
A61P 27/06

Abstract:

Optic nerve lamina region neural progenitor cells (ONLR-NPCs) are provided. Such cells secrete growth factors and survival factors that can be used in the treatment of optic nerve diseases, such as glaucoma. Also provided are methods of treating or preventing optic nerve diseases, such as glaucoma, using one or more factors secreted by ONLR-NPCs, combinations of factors secreted by ONLR-NPCs, or culture media conditioned by ONLR-NPCs.